

Date: April 29, 2026

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 544292

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: ONESOURCE

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release issued by the Company titled:

**OneSource's Partner Dr. Reddy's Laboratories receives Health
Canada Approval for Generic Semaglutide Injection**

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as below

OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection

OneSource serves as the manufacturing partner and provides scale-up and commercial manufacturing of the formulation

Bangalore, India, April 29, 2026 – OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that its partner Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.

The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru.

Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: "We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities."

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors Anurag Bhagania CFO Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com	Corporate Communication Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Abhilash Mukherjee: +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@msslgroup.com
--	--